Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107719 | 0.91 | MEN1 (0.58) | MEN1KMT2APTGS2POLBAPEX1 | |
| SCHEMBL2664258 | 0.91 | MAPT (0.53) | MEN1KMT2AMAPTHPGDRAB9A | |
| SCHEMBL2668846 | 0.86 | PTGS2 (0.49) | MEN1KMT2APTGS2POLBAPEX1 | |
| SCHEMBL12742979 | 0.86 | PTGS2 (0.46) | MAPTHPGDRAB9APTGS2POLB | |
| SCHEMBL12594254 | 0.85 | MAPT (0.47) | MEN1KMT2AMAPTHPGDRAB9A | |
| SCHEMBL2654925 | 0.85 | MEN1 (0.49) | MEN1KMT2APTGS2POLBAPEX1 | |
| SCHEMBL1107611 | 0.85 | MEN1 (0.52) | MEN1KMT2APTGS2POLBAPEX1 | |
| SCHEMBL2664242 | 0.85 | MAPT (0.47) | MEN1KMT2AMAPTHPGDRAB9A | |
| SCHEMBL1140769 | 0.83 | MEN1 (0.50) | MEN1KMT2APTGS2POLBAPEX1 | |
| SCHEMBL10949996 | 0.82 | MAPT (0.70) | MEN1KMT2AMAPTHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | MEN1 3412/4885KMT2A 2260/4885MAPT 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.